We performed a comparative analysis between our findings and previous studies investigating the prognostic significance of RUNX1 mutations in AML patients undergoing allo-HSCT, aiming to identify key factors that may account for the observed discrepancies. This evidence concerns the gene RUNX1 and acute myeloid leukemia.